Jiangsu Lanfeng Bio-chemicalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Jiangsu Lanfeng Bio-chemicalLtd şirketinin toplam hissedar öz sermayesi CN¥9.6M ve toplam borcu CN¥659.3M olup, bu da borç-öz sermaye oranını 6898.9% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥3.4B ve CN¥3.4B dir.

Anahtar bilgiler

6,898.9%

Borç/özkaynak oranı

CN¥659.33m

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥325.79m
Eşitlik	CN¥9.56m
Toplam yükümlülükler	CN¥3.42b
Toplam varlıklar	CN¥3.43b

Son finansal sağlık güncellemeleri

Güncelleme yok

Recent updates

Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

Nov 09

Benign Growth For Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Underpins Its Share Price

Sep 25

Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

Jun 07

The Market Doesn't Like What It Sees From Jiangsu Lanfeng Bio-chemical Co.,Ltd's (SZSE:002513) Revenues Yet As Shares Tumble 26%

Feb 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 002513 'nin kısa vadeli varlıkları ( CN¥1.4B ) kısa vadeli yükümlülüklerini ( CN¥2.6B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 002513 şirketinin kısa vadeli varlıkları ( CN¥1.4B ) uzun vadeli yükümlülüklerini ( CN¥800.1M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 002513 'nin net borç/öz sermaye oranı ( 3490% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 002513 şirketinin borç/öz sermaye oranı son 5 yılda 29.5% seviyesinden 6898.9% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 002513 şirketinin mevcut serbest nakit akışına göre bir yıldan az nakit akışı süresi bulunmaktadır.

Tahmini Nakit Akışı: 002513 un, serbest nakit akışı her yıl % 59.3 oranında tarihi oranda azalmaya devam ederse bir yıldan az nakit akışı süresi vardır

Jiangsu Lanfeng Bio-chemicalLtd Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 1/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Recent updates

Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Stock Catapults 107% Though Its Price And Business Still Lag The Industry

New minor risk - Share price stability

Third quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.11 loss in 3Q 2023)

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q3, 2024 Results on Oct 31, 2024

Benign Growth For Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Underpins Its Share Price

Second quarter 2024 earnings released: CN¥0.32 loss per share (vs CN¥0.20 loss in 2Q 2023)

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2024 Results on Aug 06, 2024

Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough

First quarter 2024 earnings released: CN¥0.082 loss per share (vs CN¥0.043 loss in 1Q 2023)

Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 23, 2024

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q1, 2024 Results on Apr 30, 2024

The Market Doesn't Like What It Sees From Jiangsu Lanfeng Bio-chemical Co.,Ltd's (SZSE:002513) Revenues Yet As Shares Tumble 26%

New minor risk - Share price stability

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 30, 2024

Third quarter 2023 earnings released: CN¥0.11 loss per share (vs CN¥0.006 loss in 3Q 2022)

New major risk - Financial position

Second quarter 2023 earnings released: CN¥0.20 loss per share (vs CN¥0.004 profit in 2Q 2022)

Jiangsu Lanfeng Bio-Chemical Co.,Ltd Approves Management Elections

New minor risk - Share price stability

Zheng Xu acquired a 18.04% stake in Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) from Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. for approximately CNY 300 million.

Zheng Xu acquired a 18.04% stake in Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) from Jiangsu Suhua Group Co., Ltd. and Suzhou Gelin Investment Management Co., Ltd. for approximately CNY 300 million.

Full year 2022 earnings released: CN¥0.88 loss per share (vs CN¥1.44 loss in FY 2021)

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.006 loss per share (vs CN¥0.076 loss in 3Q 2021)

First quarter 2022 earnings released: EPS: CN¥0.003 (vs CN¥0.004 in 1Q 2021)

High number of new directors

Jiangsu Lanfeng Bio-chemical Co.,Ltd, Annual General Meeting, May 10, 2022

Full year 2021 earnings released: CN¥1.44 loss per share (vs CN¥0.04 profit in FY 2020)

Third quarter 2021 earnings released: CN¥0.076 loss per share (vs CN¥0.06 profit in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.04 loss per share (vs CN¥0.017 profit in 2Q 2020)

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.004 (vs CN¥0.05 loss in 1Q 2020)

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Fiscal Year 2020 Results on Apr 20, 2021

New 90-day low: CN¥3.50

New 90-day low: CN¥3.53

New 90-day low: CN¥3.90

New 90-day high: CN¥4.37

Third quarter earnings released

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report Q3, 2020 Results on Oct 23, 2020

New 90-day high: CN¥4.30

Taicang Yunzaifei Material Trading Co., Ltd. signed an agreement to acquire Taicang Lanfeng Chemical Co., Ltd. from Jiangsu Lanfeng Bio-chemical Co.,Ltd (SZSE:002513) for CNY 10.8 million.

New 90-day low - CN¥3.86

First half earnings released

Jiangsu Lanfeng Bio-chemical Co.,Ltd to Report First Half, 2020 Results on Aug 25, 2020

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin